ALSUntangled #64: butyrates.

ALS alternative therapy butyrate gut microbiome neuroinflammation

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 1 3 2022
medline: 16 11 2022
entrez: 28 2 2022
Statut: ppublish

Résumé

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

Identifiants

pubmed: 35225121
doi: 10.1080/21678421.2022.2045323
doi:

Substances chimiques

Butyrates 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

638-643

Auteurs

Yuyao Sun (Y)

Neurology Department, Duke University, Durham, NC, USA.

Richard Bedlack (R)

Neurology Department, Duke University, Durham, NC, USA.

Carmel Armon (C)

Department of Neurology, Loma Linda University, Loma Linda, CA, USA.

Morgan Beauchamp (M)

Undergraduate, North Carolina State University, Raleigh, NC, USA.

Tulio Bertorini (T)

Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.

Robert Bowser (R)

Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.

Mark Bromberg (M)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

James Caress (J)

Department of Neurology, Baptist Medical Center, Winston Salem, NC, USA.

Gregory Carter (G)

Department of Rehabilitation, Elson S. Floyd College of Medicine, Spokane, WA, USA.

Jesse Crayle (J)

Neurology Department, Washington University, St. Louis, MO, USA.

Merit E Cudkowicz (ME)

Neurology Department, Mass General Brigham Inc, Boston, MA, USA.

Jonathan D Glass (JD)

Neurology Department, Emory University, Atlanta, GA, USA.

Carlayne Jackson (C)

Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Isaac Lund (I)

Student, Green Hope High School, Cary, NC, USA.

Sarah Martin (S)

Physical Therapy Program, Duke University, Durham, NC, USA.

Sabrina Paganoni (S)

Neurology Department, Mass General Brigham Inc, Boston, MA, USA.

Gary Pattee (G)

Department of Neurology, Nebraska Medical Center, Omaha, NE, USA.

Dylan Ratner (D)

Student, Longmeadow High School, Longmeadow, MA, USA.

Kristiana Salmon (K)

Department of Neurology, Montreal Neurological Institute, Montreal Canada.

Paul Wicks (P)

Independent Consultant, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH